In a regulatory filing, Oric Pharmaceuticals president and CEO Jacob Chacko disclosed the sale of 40,000 common shares of the company on March 6 at a price of $16.2095 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ORIC:
- ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Oric Pharmaceuticals price target raised to $20 from $12 at Wedbush
- Oric Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
- ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
